Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 5,101–5,200 of 15,747
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic
Favalli, E. G., Maioli, G., Biggioggero, M., & Caporali, R. F. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1908887 · Cited by 22
Antibody responses to COVID‐19 vaccines in older adults
Soytaş, R. B., Cengız, M., İslamoğlu, M. S., Uysal, B. B., Yavuzer, S., & Yavuzer, H. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27531 · Cited by 18
“Clinical trials demonstrated 95% efficacy in preventing symptomatic COVID‐19 12 days after the first Pfizer/BioNTech dose and 7 or more days after the second dose.(18) In a study of patients aged 70 years and older, Pfizer‐BioNTech found that a vaccine efficacy of 70% was achieved (95% confidence interval 59%–78%) 10…”
BackgroundLiu, Z., Wang, Q., Feng, Y., Zhao, L., Dong, N., Zhang, Y. X., Yin, T., He, H., Tang, X., Gou, J., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.146474 · Cited by 19
Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity
Ford, B. N., & Savitz, J. B. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00288-7 · Cited by 19
“8) Confirmed CoVID19 (symptoms in combination with PCR test) [46]”
BackgroundKassardjian, A., Sun, E., Sookhoo, J. R. V., Muthuraman, K., Boligan, K. F., Kucharska, I., Rujas, E., Jetha, A., Branch, D. R., Babiuk, S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112391 · Cited by 18
“Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December of 2019, joint efforts by the global scientific community have led to the development and deployment of vaccines at an unprecedented rate.(1,2) Currently licensed vaccines against SARS-CoV-2 have countered the advance of th…”
BackgroundDeveloping mRNA lipid nanoparticle vaccine effective for cryptococcosis in a murine model
Li, Y., Ambati, S., Meagher, R. B., & Lin, X. (2025) · npj Vaccines · doi:10.1038/s41541-025-01079-z · Cited by 21
Shah, M., Moon, S. U., Kim, J. H., Thao, T. T., & Woo, H. G. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.04.030 · Cited by 18
Yousef, M., Rob, M., Varghese, S., Rao, S., Zamir, F., Paul, P., & Châari, A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122535 · Cited by 23
Chakravarthy, K. V., Strand, N. H., Frosch, A. E. P., Sayed, D., Narra, L. R., Chaturvedi, R., Grewal, P. K., Pope, J. E., Schatman, M. E., & Deer, T. R. (2021) · Journal of Pain Research · doi:10.2147/jpr.s302115 · Cited by 19
Previously infected vaccinees broadly neutralize SARS-CoV-2 variantsPreprint
Leier, H. C., Bates, T. A., Lyski, Z. L., McBride, S. K., Lee, D. X., Coulter, F. J., Goodman, J. R., Lu, Z., Curlin, M. E., Messer, W. B., et al. (2021) · medRxiv · doi:10.1101/2021.04.25.21256049 · Cited by 19
Spike-based COVID-19 immunization increases antibodies to nucleocapsid antigen
Dobaño, C., Jiménez, A., Rubio, R., Alonso, S., Ramírez‐Morros, A., Vidal, M., Vidal‐Alaball, J., Ruiz‐Comellas, A., García‐Basteiro, A. L., Izquierdo, L., et al. (2021) · Translational research · doi:10.1016/j.trsl.2021.10.004 · Cited by 24
Development of Therapeutic RNA Manipulation for Muscular Dystrophy
Saifullah, S., Motohashi, N., Tsukahara, T., & Aoki, Y. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.863651 · Cited by 22
“Lipid nanoparticle (LNP) has been successfully used in COVID-19 vaccines (Baden et al., 2020; Polack et al., 2020), which might be an alternative approach for future DMD therapeutics.”
BackgroundMethodPépin, J., Labbé, A., Carignan, A., Parent, M., Yu, J. W., Grenier, C., Beauchemin, S., Wals, P. D., Valiquette, L., & Rousseau, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.019 · Cited by 19
Duerr, R., Dimartino, D., Marier, C., Zappile, P., Wang, G., François, F., Ortigoza, M. B., Iturrate, E., Samanovic, M. I., Mulligan, M. J., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104843 · Cited by 20
Sernicola, A., Dybała, A., Gomes, V., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17807 · Cited by 18
Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
Anichini, G., Terrosi, C., Savellini, G. G., Gandolfo, C., Franchi, F., & Cusi, M. G. (2021) · Vaccines · doi:10.3390/vaccines9050517 · Cited by 19
Li, H., Guo, L., Zheng, H., Li, J., Zhao, X., Li, J., Liang, Y., Yang, F., Zhao, Y., Yang, J., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00424 · Cited by 17
Immunisation, asymptomatic infection, herd immunity and the new variants of COVID 19Preprint
Grant, A., & Hunter, P. R. (2021) · medRxiv · doi:10.1101/2021.01.16.21249946 · Cited by 19
Tokunoh, N., Tamiya, S., Watanabe, M., Okamoto, T., Anindita, J., Tanaka, H., Ono, C., Hirai, T., Akita, H., Matsuura, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1224634 · Cited by 18
Amanzio, M., Cipriani, G. E., & Bartoli, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1900728 · Cited by 19
Polymeric Carriers for Delivery of RNA Cancer Therapeutics
Mirón‐Barroso, S., Correia, J. S., Frampton, A. E., Lythgoe, M. P., Clark, J., Tookman, L. A., Ottaviani, S., Castellano, L., Porter, A. E., Georgiou, T. K., et al. (2022) · Non-Coding RNA · doi:10.3390/ncrna8040058 · Cited by 19
“In fact, several products have reached the market including Patisiran, the first iRNA therapeutic approved by the FDA [24] and the recently developed vaccines against SARS-CoV-2 [25,26].”
BackgroundRota, M., Torresan, I., Palmerio, S., Tasselli, E., Rossi, A., Zivi, A., & Zacchi, F. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105068 · Cited by 27
Dembiński, Ł., Martins, M. V., Huss, G., Grossman, Z., Barak, S., Magendie, C., del Torso, S., Dornbusch, H. J., Mazur, A., Albrecht, K., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.721257 · Cited by 18
On the Influence of Nucleic Acid Backbone Modifications on Lipid Nanoparticle Morphology
An, K., Kurek, D. Z., Mahadeo, M., Zhang, Y., Thewalt, J. L., Cullis, P. R., & Kulkarni, J. A. (2022) · Langmuir · doi:10.1021/acs.langmuir.2c01492 · Cited by 18
Polykretis, P. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13160 · Cited by 19
A decavalent composite mRNA vaccine against both influenza and COVID-19
Wang, Y., Ma, Q., Li, M., Mai, Q., Ma, L., Zhang, H., Zhong, H., Mai, K., Cheng, N., Feng, P., et al. (2024) · mBio · doi:10.1128/mbio.00668-24 · Cited by 20
“Amid the COVID-19 pandemic, mRNA vaccines encoding the SARS-CoV-2 spike protein, not only received their initial author ization for human use but also rapidly became the most widely used globally, credi ted to their potent efficacy and expedited development timelines (13–15).”
BackgroundFedorovskiy, A. G., Antropov, D. N., Dome, A. S., Puchkov, P. A., Makarova, D. M., Konopleva, M. V., Matveeva, A. M., Panova, E. A., Shmendel, E. V., Maslov, M. A., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050684 · Cited by 19
Nguyen, K. V. (2021) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2021.1914851 · Cited by 19
Applications of multiplexed CRISPR–Cas for genome engineering
Cheng, H., Jeong, E., & Cho, S. W. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01500-6 · Cited by 30
Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19
Guerrero, A. J., Estirado, A. D., Quirós, J. C., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.07.012 · Cited by 18
“1%, respectively, in the placebo groups.(1,2) Both vaccines contain polyethylene glycol or polyoxyethylene (PEG) lipid conjugate as an excipient.”
BackgroundFerreira, L. S., de Almeida, G. B., Borges, M. E., Simon, L. M., Poloni, S., Bagattini, Â. M., da Rosa, M. Q. M., Diniz‐Filho, J. A. F., Kuchenbecker, R. D. S., Camey, S. A., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.082 · Cited by 19
The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022
Sridhar, S., Chicz, R. M., Warren, W., Tartaglia, J., Savarino, S. J., Gurunathan, S., & Toussaint, J.-F. (2022) · Nature Communications · doi:10.1038/s41467-022-33549-6 · Cited by 16
COVID-19 and Type 1 Diabetes: Addressing Concerns and Maintaining Control
DiMeglio, L. A. (2021) · Diabetes Care · doi:10.2337/dci21-0002 · Cited by 22
Ousseine, Y. M., Vaux, S., Vandentorren, S., Bonmarin, I., Champenois, K., Lydié, N., & Velter, A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19095372 · Cited by 17
“By the end of 2020, studies had shown the safety and efficacy of the Moderna and Pfizer/BioNtech mRNA vaccines [1,2].”
BackgroundCOVID-19 Vaccine Effectiveness Against Omicron Infection and Hospitalization
Piché‐Renaud, P., Swayze, S., Buchan, S. A., Wilson, S. E., Austin, P. C., Morris, S. K., Nasreen, S., Schwartz, K. L., Tadrous, M., Thampi, N., et al. (2022) · PEDIATRICS · doi:10.1542/peds.2022-059513 · Cited by 23
Bişgin, A., Şanlioğlu, A. D., Ekşi, Y. E., Griffith, T. S., & Şanlıoğlu, S. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.052 · Cited by 19
Moreno, N. F., McAdams, R., Goss, J. A., & Galván, N. T. N. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00366-1 · Cited by 21
In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein
Kathwate, G. H. (2022) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-021-10348-z · Cited by 20
Tyrkalska, S. D., Candel, S., Pedoto, A., García‐Moreno, D., Alcaraz‐Pérez, F., Sánchez‐Ferrer, Á., Cayuela, M. L., & Mulero, V. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuac042 · Cited by 20
“When these blood clots do occur, they may be in unusual or atypical locations (e.g. brain, liver, bowel, spleen) Not known: severe allergic reaction (anaphylaxis), rapid swelling under the skin in areas such as the face, lips, mouth and throat, which may cause difficulty in swallowing or breathing (angioedema), Rare:…”
BackgroundInfluentialCosta, C. S., Migliore, E., Galassi, C., Scozzari, G., Ciccone, G., Coggiola, M., Pira, E., Scarmozzino, A., Valle, G. L., Cassoni, P., et al. (2022) · Vaccines · doi:10.3390/vaccines10030474 · Cited by 19
“The COVID-19 mRNA vaccines were the first to receive emergency use authorization from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).”
ResultInfluentialT-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination
Notarbartolo, S. (2024) · Vaccines · doi:10.3390/vaccines12101126 · Cited by 23
“According to the results from phase III clinical trials, the protection against the wild-type SARS-CoV-2-induced disease ranges from 94 to 95% of two doses of mRNA-based vaccines [124,125] to 67–74% of one or two doses of adenoviral vector-based vaccines [126,127].”
Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses
Huayamares, S. G., Lian, L., Rab, R., Hou, Y., Radmand, A., Kim, H., Zenhausern, R., Achyut, B. R., Gilbert‐Ross, M., Lokugamage, M. P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58548-1 · Cited by 19
Protein engineering responses to the COVID-19 pandemic
Hsieh, C., & McLellan, J. S. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102385 · Cited by 17
Li, H., Cheng, C., Shi, S., Wu, Y., Gao, Y., Liu, Z., Liu, M., Li, Z., Huo, L., Pan, X., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114426 · Cited by 21
Predictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Frölke, S. C., Bouwmans, P., Messchendorp, A. L., Geerlings, S. E., Hemmelder, M. H., Gansevoort, R. T., Hilbrands, L. B., Reinders, M. E. J., Sanders, J., Bemelman, F. J., et al. (2022) · Transplantation Direct · doi:10.1097/txd.0000000000001397 · Cited by 17
Exploring the possible link between myocarditis and mRNA COVID-19 vaccines
Sinagra, G., Merlo, M., & Porcari, A. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.08.018 · Cited by 17
Lipid nanoparticle steric stabilization roadmap
Cai, X., Zhai, J., Tran, N. L., Mulet, X., & Drummond, C. J. (2022) · Advances in biomembranes and lipid self-assembly · doi:10.1016/bs.abl.2022.05.003 · Cited by 22
Jayagobi, P. A., Ong, C., Yeo, K. T., Lim, C. C. W., Seet, M. J., Kwek, L. K., Ku, C. W., Chan, J. K. Y., Mathur, M., & Chua, M. C. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2021-259 · Cited by 33
“However, only 32.9% of pregnant women reported being aware that the vaccine was efficacious in reducing the risk of COVID‑19 in pregnant women [Table 2].”
BackgroundInfluentialModified Nucleotides for Chemical and Enzymatic Synthesis of Therapeutic RNA
Graczyk, A., Radzikowska‐Cieciura, E., Kaczmarek, R., Pawłowska, R., & Chworoś, A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221014111403 · Cited by 19
Eid, J., Abdelwahab, M., Williams, H., Caplan, M., Hajmurad, S., Venkatesh, K. K., Costantine, M. M., & Rood, K. M. (2022) · American Journal of Reproductive Immunology · doi:10.1111/aji.13596 · Cited by 19
Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infectionPreprint
Weekes, M. P., Weekes, M., Jones, N. K., et al. (2021) · doi:10.22541/au.161420511.12987747/v1 · Cited by 18
Brunner, W. M., Freilich, D., Victory, J. M., Krupa, N. L., Scribani, M., Jenkins, P., Lasher, E. G., Fink, A., Shah, A., Cross, P., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.022 · Cited by 21
Choi, M. J., Na, Y., Hyun, H., Nham, E., Yoon, J. G., Seong, H., Seo, Y. B., Choi, W. S., Song, J. Y., Kim, D. W., et al. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.12.010 · Cited by 23
Eales, O. D., Wang, H., Haw, D., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010724 · Cited by 18
“Since the development of effective vaccines [5,6], vaccination has been at the forefront of public health interventions in many populations.”
BackgroundZhu, D. Y., Gorman, M. J., Yuan, D., Yu, J., Mercado, N. B., McMahan, K., Borducchi, E. N., Lifton, M. A., Liu, J., Nampanya, F., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001609 · Cited by 19
(2021) · doi:10.1101/2021.06.01.21258172 · Cited by 425
Amiya, S., Fujimoto, J., Matsumoto, K., Yamamoto, M., Yamamoto, Y., Yoneda, M., Kuge, T., Miyake, K., Shiroyama, T., Hirata, H., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.031 · Cited by 20
Kowalczyk, A. (2024) · Medicina · doi:10.3390/medicina60060892 · Cited by 24
Ramos, A., Cardoso, M. J., Ribeiro, L., & Guimarães, J. T. (2022) · Diagnostics · doi:10.3390/diagnostics12010205 · Cited by 20
“However, it has several limitations: the number of participants is small; COVID-19 patients were not evaluated; only one type of vaccine was included; and the NAbs determination method is not the gold standard.”
BackgroundInfluentialPandey, M., Ozberk, V., Eskandari, S., Shalash, A. O., Joyce, M., Saffran, H. A., Day, C. J., Lepletier, A., Spillings, B. L., Mills, J.-L. S., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1260 · Cited by 17
Population-Wide Persistent Hemostatic Changes After Vaccination With ChAdOx1-S
de Laat, B., Stragier, H., Kremers, R., Ninivaggi, M., Mesotten, D., Thiessen, S., Pelt, K. V., Roest, M., Penders, J., Vanelderen, P., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.966028 · Cited by 18
Upadhyay, V., Patrick, C., Lucas, A., & Mallela, K. M. G. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00132 · Cited by 19
Capuano, R., Donnarumma, G., Bisecco, A., et al. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211038111 · Cited by 18
Mondal, A. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100754 · Cited by 18
Ronchini, C., Gandini, S., Pasqualato, S., Mazzarella, L., Facciotti, F., Mapelli, M., IEO Covid Team, Frigè, G., Passerini, R., Pase, L., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263014 · Cited by 22
“0001; Table 2), confirming the effectiveness of vaccination [4-9].”
BackgroundAbdulgayoom, M., Albuni, M. K., Abdelmahmuod, E. A., et al. (2021) · Clinical Case Reports · doi:10.1002/ccr3.5003 · Cited by 18
Educational Impact of #IDJClub, a Twitter-Based Infectious Diseases Journal Club
Schwartz, I. S., McCarty, T. P., Woc-Colburn, L. E., Titanji, B. K., Cutrell, J. B., & Cortes-Penfield, N. W. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac108 · Cited by 18
Bernal, J. A. L., Andrews, N., Gower, C., Stowe, J., Tessier, E., Simmons, R., & Ramsay, M. (2021) · medRxiv · doi:10.1101/2021.05.14.21257218 · Cited by 19
“Introduction Real world effectiveness data has begun to emerge for COVID-19 vaccines, showing high levels of protection against both symptomatic and asymptomatic infection, supporting the findings of the phase III clinical trials.(1-6) Nevertheless, evidence on effectiveness against mortality, the most severe outcome,…”
BackgroundHuang, P., Liu, T., Wu, J., Tsai, Y., & Lai, C. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28621 · Cited by 20
“During the fight against COVID‐19, several novel vaccines that provide effective protection against SARS‐CoV‐2 infection were rapidly developed.(4,5) However, the preventive effects of COVID‐19 vaccines gradually decrease and new SARS‐ CoV‐2 variants are appearing.”
BackgroundCOVID-19 Vaccination Strategy for Ontario Using Age and Neighbourhood-Based Prioritization
Brown, K. A., Stall, N. M., Joh, E., Allen, U., Bogoch, I. I., Buchan, S. A., Daneman, N., Evans, G. A., Fisman, D. N., Gibson, J. L., et al. (2021) · doi:10.47326/ocsat.2021.02.10.1.0 · Cited by 27
Morrocchi, E., Pighi, C., Pascucci, G. R., Cotugno, N., Medri, C., Amodio, D., Colagrossi, L., Ruggiero, A., Manno, E. C., Tumeo, C. C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac408 · Cited by 19
“40 000 participants [7], to our knowledge data in this study regarding the 196 HIV-positive (HIV+) individuals included in the cohort have yet to be published.”
Matsuda, M., Asanuma, Y., Yokota, K., Sakai, S., Yazawa, H., Maruyama, T., Wada, T. T., Araki, Y., & Mimura, T. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0590-22 · Cited by 22
“The results of randomized clinical trials have shown that the BNT162b2 mRNA COVID-19 vaccine and the mRNA-1273 COVID-19 vaccine are 95% and 94% effective, respectively, in preventing the onset of COVID-19 (2, 3).”
BackgroundLuo, J., Zhang, Z., Song, Z., & Gao, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076369 · Cited by 23
Long Term Immune Response Produced by the SputnikV Vaccine
Martynova, E. V., Hamza, S., Garanina, E. E., Kabwe, E., Markelova, M., Shakirova, V. G., Хаертынова, И. М., Kaushal, N., Baranwal, M., Rizvanov, A. A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011211 · Cited by 19
Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models
Yang, H., Cao, J. A., Lin, X., Yue, J., Zieneldien, T., Kim, J., Wang, L., Fang, J., Huang, R., Bai, Y., et al. (2022) · Viruses · doi:10.3390/v14030449 · Cited by 19
“Alternatively, mRNA-based vaccines are a novel approach for infectious diseases and are currently the dominant approach in fighting COVID-19 [57].”
BackgroundModeling of Vaccination and Contact Tracing as Tools to Control the COVID-19 Outbreak in Spain
Colomer, M. À., Margalida, A., Alòs, F., Oliva‐Vidal, P., Vilella, A., & Fraile, L. J. (2021) · Vaccines · doi:10.3390/vaccines9040386 · Cited by 17
Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
Andersen, T. K., Bodin, J., Oftung, F., Bogen, B., Mjaaland, S., & Grødeland, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.747032 · Cited by 18
Hashimoto, T., Ozaki, A., Bhandari, D., Sawano, T., Sah, R., & Tanimoto, T. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab090 · Cited by 17
“The BNT162b2 mRNA COVID-19 vaccine (Comirnaty, Pfizer-BioNTech, USA) is one of the vaccines granted earliest regulatory approval globally.(2) ,3 In Japan, fasttrack approval was granted to the vaccine on 14 February 2021, with the scheduled provision of ∼140 million doses.”
BackgroundPost-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica
Januel, É., Seze, J. D., Vermersch, P., Maillart, É., Bourre, B., Pique, J., Moisset, X., Bensa, C., Maarouf, A., Pelletier, J., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211049737 · Cited by 18
“Three patients without prior COVID-19 infection developed symptoms within 7 days after the second vaccine dose, thus before obtaining vaccine full efficacy based on the BNT162b2 randomized trial(9).”
Gauci, M.-L., Coutzac, C., Houot, R., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.003 · Cited by 17
Ramsay Hunt syndrome following COVID-19 vaccination
Woo, C. J., Chou, O. H. I., & Cheung, B. M. Y. (2022) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2021-141022 · Cited by 17
Antibody kinetics and clinical course of COVID-19 a prospective observational study
Bläckberg, A., Fernström, N., Sarbrant, E., Rasmussen, M., & Sunnerhagen, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248918 · Cited by 20
Alijotas‐Reig, J., Garcia-Gimenez, V., Velthuis, P. J., Niessen, F. B., & Decates, T. S. (2022) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.15117 · Cited by 17
Autopsy findings of post-COVID-19 vaccination deaths in Tokyo Metropolis, Japan, 2021
Suzuki, H., Ro, A., Takada, A., Saito, K., & Hayashi, K. (2022) · Legal Medicine · doi:10.1016/j.legalmed.2022.102134 · Cited by 20
“The BNT162b2 (Comirnaty, BioNTech/Pfizer) and mRNA-1273 (Spikevax, Moderna) mRNA-based vaccines have demonstrated a high efficacy rate [4,5].”
Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy
Kim, H. J., Seo, S. K., & Park, H. Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.029 · Cited by 19
Chi, G., Montazerin, S. M., Lee, J., Kazmi, S. H. A., Shojaei, F., Fitzgerald, C., & Gibson, C. M. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27259 · Cited by 17
Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL
Benjamini, O., Gershon, R., Bar‐Haim, E., Lustig, Y., Cohen, H., Doolman, R., Kedmi, M., Ribakovsky, E., Kneller, A., Hod, T., et al. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13878 · Cited by 18
Braun, E., Horowitz, N. A., Leiba, R., Weissman, A., Mekel, M., Shachor‐Meyouhas, Y., Hussein, K., Halberthal, M., Azzam, Z. S., & Berger, G. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.07.002 · Cited by 16
“This vaccine was found to be effective in reducing the number of people infected with SARS-CoV-2 and contributed to fewer cases of severe disease [1].”
Picazo, J. J. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/085.2021 · Cited by 32
mRNABERT: advancing mRNA sequence design with a universal language model and comprehensive dataset
Xiong, Y., Wang, A., Kang, Y., Shen, C., Hsieh, C., & Hou, T. (2025) · Nature Communications · doi:10.1038/s41467-025-65340-8 · Cited by 32
A framework for monitoring population immunity to SARS-CoV-2
Lopman, B. A., Shioda, K., Nguyen, Q., Beckett, S. J., Siegler, A. J., Sullivan, P. S., & Weitz, J. S. (2021) · Annals of Epidemiology · doi:10.1016/j.annepidem.2021.08.013 · Cited by 17
David, S. S. B., Gez, S. B., Rahamim‐Cohen, D., Shamir-Stein, N., Lerner, U., & Zohar, A. E. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.13.2100540 · Cited by 18
“fatigue and headache after the second dose were reported by 59% and 52%, respectively, among younger vaccine recipients and by 51% and 39% among older recipients in the clinical trial [7].”
BackgroundCancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients
Gundavda, M. K., & Gundavda, K. K. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00903-7 · Cited by 16
Zhou, H., Ni, W., Huang, W., Wang, Z., Cai, M., & Sun, Y.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834942 · Cited by 22
“Currently, two mRNA vaccines have been approved for marketing, namely BNT162b2 developed by BioNTech & Pfizer and mRNA-1273 produced by Moderna (175, 177).”
MethodKiem, C. T., Andronico, A., Bosetti, P., Paireau, J., Alter, L., Boëlle, P., Fontanet, A. L., Lévy-Bruhl, D., & Cauchemez, S. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.26.2100533 · Cited by 17
“We assumed that mRNA vaccines (Comirnaty, BioNTech/ Pfizer, Mainz, Germany/New York, United States (US) [6] and Spikevax, Moderna, Cambridge, US [7]) are used in the entire adult population (18 years and older) and that the viral vector COVID-19 vaccine Janssen (Ad26.”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.